Filing summary
Source and period: The supplied 10-Q is for PerkinElmer, Inc., for the three months ended March 30, 2014, with comparison to the three months ended March 31, 2013. It is not a filing under the name Revvity, Inc.; investors should verify the issuer identity and filing before relying on this summary.
Business context and reporting period
PerkinElmer reported two continuing operating segments: Human Health, serving diagnostics and research markets, and Environmental Health, serving environmental, industrial, and laboratory-services markets. The unaudited quarter is the first quarter of fiscal 2014.
Financial performance
| Metric | Q1 2014 | Q1 2013 |
|---|---|---|
| Revenue | $531.9 million | $505.4 million |
| Gross profit / gross margin | $235.5 million / 44.3% | $224.9 million / 44.5% |
| Operating income / margin | $50.7 million / 9.5% | $35.9 million / 7.1% |
| Income from continuing operations | $34.3 million | $32.3 million |
| Net income | $34.2 million | $32.2 million |
| Diluted EPS | $0.30 | $0.28 |
| Operating cash flow from continuing operations | $67.9 million | $11.1 million |
| Capital expenditures | $6.0 million | $11.8 million |
| Cash and cash equivalents at period end | $224.1 million | $125.9 million |
Revenue increased 5%. Product revenue was $365.5 million and service revenue was $166.4 million. Cost of revenue grew faster than sales, reducing gross margin by 22 basis points; operating margin expanded by 243 basis points, mainly reflecting cost-containment and productivity initiatives. The 2013 comparison included $12.5 million of discrete tax benefits, versus $2.0 million in 2014, contributing to the higher 2014 effective tax rate.
Human Health revenue rose 6% to $299.5 million and segment operating income increased to $43.1 million from $25.0 million. Environmental Health revenue rose 4% to $232.4 million and segment operating income increased to $21.5 million from $20.7 million. Human Health growth reflected diagnostics and research offerings; Environmental Health growth was driven by laboratory services, including OneSource.
Balance sheet, debt, and liquidity
At March 30, 2014, total assets were $4.0 billion and total liabilities were $1.9 billion. Current assets were $1.10 billion against current liabilities of $605.5 million. Debt comprised $2.6 million of short-term debt and $926.9 million of long-term debt; cash exceeded the prior year-end balance by $50.9 million. The company had $296.0 million of additional borrowing capacity under its $700 million revolving credit facility and reported compliance with applicable covenants.
The company refinanced its revolving facility in January 2014, extending initial maturity to January 8, 2019. It had $392.0 million outstanding under that facility at quarter-end, at a disclosed effective Eurocurrency rate of 1.26%. It also had $500 million principal amount of 5% senior notes due in 2021 and $40.0 million of financing-lease obligations. Approximately $216.7 million of cash was held by non-U.S. subsidiaries; the filing says U.S. taxes could apply to repatriating approximately $194.4 million without appropriate planning.
Cash flow and capital allocation
Operating cash flow improved substantially year over year, aided by collections and lower cash outflows for accrued expenses and other items; the filing also identifies a $37.0 million U.S. pension contribution and prepaid royalties in the 2013 comparison. Investing cash use was $6.0 million, primarily capital expenditures. Financing cash use was $11.5 million, including $7.9 million of dividends and $3.9 million of share withholding repurchases. The quarterly dividend remained $0.07 per share; a second-quarter dividend of the same amount was declared after quarter-end.
Outlook, commentary, and material risks
- Management expected demand to benefit from continued growth in screening, research informatics, and laboratory services, and cited potential demand for testing solutions as contaminant regulations and protocols develop. These are management expectations, not quantified revenue guidance.
- Management expected restructuring actions undertaken in fiscal 2013 to generate more than $9 million of annual cost savings beginning in fiscal 2015, primarily through lower R&D expense.
- Product mix pressured gross margin, while cost containment and productivity initiatives supported operating-margin improvement. Fiscal 2014 R&D expense declined 14%, partly attributed to consolidation into a new Center for Innovation.
- Restructuring and contract-termination charges were $2.1 million in the quarter. Accrued restructuring and contract obligations include facility costs extending as far as fiscal 2022; certain major 2013-plan payments continue through fiscal 2019.
- The company disclosed $13.7 million accrued for known environmental remediation matters. It stated that the Enzo patent and related litigation trial was delayed from March but was still expected in 2014; $3.2 million of trial-preparation costs was incurred in the quarter. Management did not expect a material adverse financial-statement effect, while acknowledging uncertainty.
- Key risks include market and government-funding volatility, foreign exchange exposure, competition and product development, supply interruptions, regulatory compliance, litigation, pension funding, substantial debt and variable-rate interest exposure, and possible impairment of goodwill and other intangibles. One goodwill reporting unit had fair value only about 11% above carrying value at the annual test; no impairment was recorded.
Most important facts for investors to verify
- Confirm issuer identity: the source document names PerkinElmer, Inc., despite the request metadata naming Revvity, Inc.
- Assess whether the operating-income improvement is sustainable given lower gross margin, restructuring actions, and reduced R&D spending.
- Review working-capital trends and cash-flow comparability, including the prior-year pension contribution and timing-related accrual movements.
- Monitor debt balances, variable-rate borrowing costs, covenant headroom, and the availability and location of cash.
- Track the Enzo litigation, environmental remediation estimates, restructuring cash payments, and the expected realization of stated cost savings.
- Review the company’s end-market assumptions, foreign-exchange exposure, and sensitivity of the near-margin goodwill reporting unit to forecast changes.